Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
    Meeting Abstract

    Hong, D. S.; Bang, Y. J.; Barlesi, F.; Durm, G. A.; Falchook, G. S.; Govindan, R.; Dy, G. K.; Park, K.; Strickler, J. H.; Burns, T. F.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins)
    Meeting Abstract

    Riely, G. J.; Neal, J. W.; Camidge, D. R.; Spira, A.; Piotrowska, Z.; Horn, L.; Costa, D. B.; Tsao, A.; Patel, J.; Gadgeel, S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • MEDI1191, a novel IL-12 mRNA therapy for intratumoral (IT) injection for advanced solid tumours
    Meeting Abstract

    Marron, T.; Subbiah, V.; Hamid, O.; Goel, S.; Hellmann, M. D.; Carneiro, B. A.; Pate, S. P.; de Vries, E.; Luheshi, N.; Hamid, O.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO + IPI) or NIVO alone
    Meeting Abstract

    Robert, C.; Long, G. V.; Larkin, J.; Wolchok, J. D.; Hassel, J. C.; Schadendorf, D.; Hodi, F. S.; Lebbé, C.; Grob, J. J.; Grossmann, K.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Non-progression with avelumab treatment in patients with metastatic Merkel cell carcinoma (mMCC) is associated with a clinically meaningful better health-related quality of life compared with progressive disease
    Meeting Abstract

    Bharmal, M.; Nolte, S.; Lebbé, C.; Mortier, L.; Brohl, A. S.; Fazio, N.; Grob, J. J.; Prinzi, N.; Hanna, G. J.; Hassel, J.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Real world (RW) sequencing outcomes with immunotherapy and targeted therapy (TT) in BRAF+ metastatic melanoma (The NOBLE study series)
    Meeting Abstract

    Betof Warner, A.; Tarhini, A. A.; Johnson, M.; Kang, B.; Nakasato, A.; Vance, M.; Ling, Y. L.; Tang, J.; Patel, J.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
    Meeting Abstract

    Ferrarotto, R.; Wirth, L. J.; Muzaffar, J.; Rodriguez, C. P.; Xia, B.; Perez, C. A.; Bowles, D. W.; Winquist, E.; Hotte, S. J.; Metcalf, R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • SPEARHEAD-2 trial design: A phase II pilot trial of ADP-A2M4 in combination with pembrolizumab in patients with recurrent or metastatic head and neck cancer
    Meeting Abstract

    Cohen, E. E.; Dunn, L.; Neupane, P.; Gibson, M.; Leidner, R.; Savvides, P.; Hyland, N.; Trivedi, T.; Dudley, M.; Biswas, S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements
    Meeting Abstract

    Abou-Alfa, G. K.; Borbath, I.; Cohn, A. L.; Goyal, L.; Lamarca, A.; Macarulla, T.; Oh, D. Y.; Roychowdhury, S.; Sadeghi, S.; Shroff, R. T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Clinical experience of tabelecleucel in patients with EBV+ primary (PID) or acquired immunodeficiency (AID) associated lymphoproliferative disease
    Meeting Abstract

    Nikiforow, S.; Baiocchi, R.; Nasta, S.; Weng, W.; Loeb, D.; Mahadeo, K. M.; Whangbo, J.; Phuong, P.; Navarro, W.; Gamelin, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save